Lu-177-Rituximab
177Lu-Rituximab is the Lutetium-177 labeled analogue of 131I-Tositumomab (131I-Bexxar) for [...]
Lu-177-PSMA-ALB-56
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]
Lu-177-PNT6555
177Lu-PNT6555 (part of the PNT2004 development program) is a molecule [...]
Y-90-Tabituximab barzuxetan
90Y-Tabituximab barzuxetan (90Y-OTSA101-DTPA) is a radiolabeled drug based on an [...]
Ac-225-FPI-2059
225Ac-FPI-2059 (225Ac-3BP-227, 225Ac-IPN-01087) is the 225Ac-labeled analogue of 177Lu-IPN-1087, a [...]
Bi-213-DOTATOC
213Bi-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC. This [...]
At-211-BC8-B10
211At-BC8-B10 is a radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal [...]
Lu-177-Ludotadipep
177Lu-Ludotadipep (177Lu-FC705) is a 177Lu-labeled analogue of 177Lu-Vipivotide targeting PSMA. [...]
Tb-161-PSMA-I&T
161Tb-PSMA-I&T is a terbium analogue of 177Lu-Vipivotide tetraxetan and the [...]
Y-90-FAPI-04
90Y-FAPi-04 is the therapeutic analogue of the PET imaging agent [...]